We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Greiner Bio-One

The Preanalytics division develops, manufactures and distributes venous blood collection devices for hospitals, labor... read more Featured Products: More products

Download Mobile App





Greiner Bio-One Introduces Next Generation Urine Diagnostics

By LabMedica International staff writers
Posted on 29 Jul 2025

Greiner Bio-One (Kremsmünster, Austria) is exhibiting its latest advancements at ADLM 2025, which also marks the debut of its new urinalysis tube that offers room-temperature sample stability up to 72 hours. More...

At ADLM 2025, Greiner Bio-One will debut the VACUETTE Urine STB tube, which offers a standardized solution to ensure the stability of urinalysis samples by ensuring sample integrity. The all-new VACUETTE Urine STB Tube stabilizes key parameters for dipstick testing, clinical chemistry, and urine sediment analysis for up to 72 hours without refrigeration. VACUETTE Urine STB tubes contain a preservative made up of ethylparaben, chlorhexidine, and sodium propionate to inhibit bacterial and yeast growth and ensure the reliability of urinalysis results. This means a slow or delayed processing time during transport and storage will not affect the sample when it comes to sample quality and reliable analysis results, preventing the risk of preanalytical errors. The vacuum in the tube enables the optimal ratio of specimen sample to preservative. The tubes are available with a round or conical bottom for easier manual processing of the urinary sediment for microscopy analysis.

Greiner Bio-One is also sponsoring an Industry Workshop presented by Prof. Ana-Maria Simundic on the value that labs can deliver through patient blood management. Hospitalized patients are at high risk for developing hospital-acquired anemia (HAA). This session will focus on the methods labs may use to minimize patient blood loss and reduce HAA risk. Attendees will learn about the current landscape of patient blood management, explore available strategies and tools for minimizing patient blood loss, and discover possible benefits that may be achieved by implementing patient blood management interventions.

Related Links:
Greiner Bio-One


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
POCT RT-qPCR Analyzer
BG-X6
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.